2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-178177
    SDH-IN-31 98%
    SDH-IN-31 is a succinate dehydrogenase (SDH) inhibitor with an IC50 of 1.11 μM. SDH-IN-31 exhibits anti-fungal activity. SDH-IN-31 can be used for the research of infection, such as infection, such as rice sheath blight.
    SDH-IN-31
  • HY-178201
    JLJ648
    JLJ648 is a Gag-Pol dimerizer with antiviral activity. JLJ648 can inhibit HIV replication and induce infected cell pyroptosis. JLJ648 can be used for the research of infection, such as HIV (human immunodeficiency virus).
    JLJ648
  • HY-178255
    Xanthochymol 52617-32-0
    Xanthochymol is an antifungal agent found in Clusia rosea. Xanthochymol can induce fungal apoptosis.
    Xanthochymol
  • HY-178341
    NNRT-IN-13
    NNRT-IN-13 is a potent non-nucleoside reverse transcriptase (NNRT) inhibitor that directly inhibiting HIV-1 reverse transcriptase (IC₅₀ = 0.25 μM). NNRT-IN-13 exhibits excellent antiviral activity against wild-type HIV-1 (EC₅₀ = 0.0046 μM) and a broad spectrum of drug-resistant mutants. NNRT-IN-13 exhibits favorable in vivo metabolic and safety profiles. NNRT-IN-13 can be used for human immunodeficiency virus (HIV) research.
    NNRT-IN-13
  • HY-178347
    Debio 1453 2422053-29-8 98%
    Debio 1453 is a bactericidal FabI inhibitor potent against N. gonorrhoeae (IC50 = 0.6 nM), including drug-resistant strains. Debio 1453 demonstrates a low propensity for resistance selection and is effective in eradicating both planktonic and intracellular bacteria through a mechanism of concurrently inhibiting FabI and engaging the non-mutable NADH cofactor. Debio 1453 clears antibiotic-resistant N. gonorrhoeae infection in a murine vaginal model. Debio 1453 can be used for gonorrhoea research.
    Debio 1453
  • HY-178374
    BACE-1/Mpro-IN-1
    BACE-1/Mpro-IN-1 is a high brain-penetrant BACE-1 (IC50 = 0.26 μM) and SARS-CoV-2 Mpro (IC50 = 0.91 μM) dual inhibitor. BACE-1/Mpro-IN-1 binds to the aspartyl protease and cysteine protease as a mixed-type inhibitor. BACE-1/Mpro-IN-1 exhibits the most favorable docking score and a strong interaction profile. BACE-1/Mpro-IN-1 can be used for the study of COVID-19 exacerbated Neuroinflammation and Alzheimer’s disease.
    BACE-1/Mpro-IN-1
  • HY-178447
    PPARγ agonist 20
    PPARγ agonist 20 is a potent, orally active PPAR-γ agonist. PPARγ agonist 20 effectively increases antioxidant defenses (SOD, GSH) and reduces lipid peroxidation. PPARγ agonist 20 can upregulate of Pparg, Glut4, and AdipoQ, suppresses of TNF-α, IL-6, and NF-κB p65. PPARγ agonist 20 significantly lowers fasting blood glucose, improving glucose tolerance, and restoring metabolic balance in Streptozotocin (HY-13753)-Nicotinamide (HY-B0150)-induced diabetic rats. PPARγ agonist 20 can be used for the study of type 2 diabetes.
    PPARγ agonist 20
  • HY-178488
    BRM/BRG1 ATP-IN-7 2468048-19-1
    BRM/BRG1 ATP-IN-7 (Compound Cpd69) is a selective dual BRM (SMARCA2) and BRG1 (SMARCA4) inhibitor with IC50 values of 12 nM and 8 nM, respectively. BRM/BRG1 ATP-IN-7 is promising for research of BRM/BRG1-dependent cancers (e.g., non-small cell lung cancer, Ewing sarcoma) and virus-associated diseases (e.g., HPV infection).
    BRM/BRG1 ATP-IN-7
  • HY-178690
    MyD88-IN-4 1801552-15-7
    MyD88-IN-4 is a MyD88 inhibitor. MyD88-IN-4 exerts antiviral effects by up-regulating IFN-β, and anti-inflammatory effects by inhibiting pro-inflammatory cytokine production. MyD88-IN-4 prevents MyD88 homodimer formation and its interaction with IRF3/IRF7. MyD88-IN-4 demonstrates efficacy against encephalitic alphavirus infections by reducing viral replication and improving survival in VEEV TC-83-infected mouse models. MyD88-IN-4 can be used for the study of alphavirus infections, bacterial toxin-related diseases, and sepsis.
    MyD88-IN-4
  • HY-178722
    Deferasirox methyl ester 1266741-05-2 98.40%
    Deferasirox methyl ester (compound 6a), a derivative of Deferasirox (HY-17359), is an antimicrobial agent. Deferasirox methyl ester exhibits activities against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Candida albicans and Aspergillus niger with MICs of 0.5, 4.0, 1.0, 4.0, and 2.0 μg/mL, respectively. Deferasirox methyl ester can be used for antimicrobial research.
    Deferasirox methyl ester
  • HY-178724
    Mollicellin K 1179374-63-0
    Mollicellin K is a depsidone that can be isolated from the fungus Chaetomium brasiliense. Mollicellin K exhibits antimicrobial activity against Myobacterium tuberculosis, antimalarial activity (IC50 = 1.2 μM) against Plasmodium falciparum as well as antifungal property (IC50 = 1.2 μM) against Candida albicans. Mollicellin K is cytotoxic against KB (IC50 = 1.9 μM), BC1 (IC50 = 6.8 μM), NCI-H187 (IC50 = 0.35 μM), and five cholangiocarcinoma cell lines. Mollicellin K also has an MIC of 12.5 μM for tuberculosis.
    Mollicellin K
  • HY-178728
    BION106 3077918-44-3 98%
    BION106 is a dihydrofolate reductasethymidylate synthase (DHFR-TS) PROTAC degrader. BION106 exhibits extremely strong anti-malarial activity with a Ki and toxicity of 2.68 nM and 0.2 μM against Plasmodium falciparum, and > 100 μM and 44.2 μM in mammalian cells. BION106 can be used for the study of antimalarial parasites (Blue: Idasanutlin ligand (HY-15676); Pink: DHFR-TS ligand (HY-153007); Black: Linker (HY-W021401)).
    BION106
  • HY-178732
    AB-22 1463913-43-0 98%
    AB-22, a vinyl sulfate compound, is an orally active antifungal agent. AB-22 inhibits hyphal growth and biofilm initiation by inhibiting the gene expression of ALS3, HWP1, and ECE1 in Candida albicans SC5314 cells. AB-22 can be used for the research of infrction, such as systemic candidiasis.
    AB-22
  • HY-178738
    GC-072 1371629-36-5 98%
    GC-072 is an orally active, 4-oxoquinolizine antibiotic that selectively inhibits bacterial DNA gyrase and Topo IV enzymes. GC-072 does not inhibit human topoisomerases I and II. GC-072 demonstrates strong antimicrobial activity against various bacterial strains, including Gram-positive, Gram-negative, and resistant bacteria. GC-072 also exhibits bactericidal activity against Burkholderia pseudomallei both extracellularly and intracellularly, leading to dose-dependent survival in mice exposed to lethal inhalational models of B. pseudomallei infection. GC-072 can be used for the research of melioidosis.
    GC-072
  • HY-178741
    KFA-027
    KFA-027 is a HIV-1 inhibitor, with an IC50 of 0.398 nM. KFA-027 inhibits capsid-dependent early steps (reverse transcription, nuclear import, integration) and late-stage aberrant capsid assembly in the HIV-1 replication cycle. KFA-027 can be used for the study of multidrug-resistant HIV-1 infections.
    KFA-027
  • HY-178759
    DHFR-IN-5-amino-PEG3-C2-azido 3077918-53-4
    DHFR-IN-5-amino-PEG3-C2-azido is a synthesized E3 ligase ligand-linker conjugate that can be used to synthesize BION106 (HY-178728). BION106 is a potent DHFR-TS PROTAC degrader with anti-malarial activity.
    DHFR-IN-5-amino-PEG3-C2-azido
  • HY-178772
    SARS-CoV-2 Mpro-IN-50 3038701-72-0
    SARS-CoV-2 Mpro-IN-50 (Compound 30) is a noncovalent SARS-CoV-2 Mpro inhibitor with an IC50 of 14  nM. SARS-CoV-2 Mpro-IN-50 is also a pan-CoV Mpro inhibitor with IC50 s of 20-190 nM for SARS-CoV-1 Mpro, 229E Mpro, HKU1 Mpro, MERS Mpro, NL63 Mpro and OC43 Mpro. SARS-CoV-2 Mpro-IN-50 has significant antiviral activity against the SARS-CoV-2 omicron variant (EC50 : 22  nM). SARS-CoV-2 Mpro-IN-50 can be used for coronavirus infections research.
    SARS-CoV-2 Mpro-IN-50
  • HY-178784
    Antileishmanial agent-37
    Antileishmanial agent-37 (Compound 1b) is an antileishmanial agent, TbPTR1 (an IC50 value of 17.1 μM) and LmPTR1 inhibitor. Anti-leishmaniasis agent-37 has a moderate effect against Leishmania infantum.
    Antileishmanial agent-37
  • HY-178785
    Anti-infective agent 11
    Anti-infective agent 11 (Compound 19) is an orally active antiparasitic agent. Anti-infective agent 11 inhibits the proteolytic activity of P. falciparum. Anti-infective agent 11 exhibits inhibitory activity against P. falciparum 3D7 with an IC50 of 0.28 μM.
    Anti-infective agent 11
  • HY-178802
    Antitubercular agent-53 98%
    Antitubercular agent-53 (Compound 5b) is an antitubercular agent and antibacterial agent. Antitubercular agent-53 shows antitubercular activity against M. tuberculosis H37RV with an MIC of 4 μg/mL.
    Antitubercular agent-53
Cat. No. Product Name / Synonyms Application Reactivity